Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF 3.200
+0.060 (1.91%)
Nov 28, 2025, 5:31 PM CET
Molecular Partners AG Revenue
In the year 2024, Molecular Partners AG had annual revenue of 4.97M CHF, down -29.38%.
Revenue
4.97M
Revenue Growth
-29.38%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
119.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
Molecular Partners AG News
- 17 days ago - Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript - Seeking Alpha
- 18 days ago - Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action - GlobeNewsWire
- 27 days ago - Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 - GlobeNewsWire
- 27 days ago - Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 4 weeks ago - Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 - GlobeNewsWire
- 3 months ago - Looking Into Molecular Partners's Recent Short Interest - Benzinga
- 3 months ago - Molecular Partners (MOLN) Stock Rating Maintained by JP Morgan | MOLN Stock News - GuruFocus
- 3 months ago - EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga